• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Veev Bolsters C-Suite, Appoints Gordon Heneweer as CFO

    4/4/22 9:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    SAN MATEO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Today Veev, the technology-enabled homebuilding company, announced the latest addition to its leadership team, naming Gordon Heneweer as Chief Financial Officer. Heneweer will oversee all finance and accounting functions including the Corporate Controllership, FP&A, project finance, Treasury, Tax and business operations, as well as corporate strategy.

    Veev has achieved a novel approach to homebuilding that views the home as the ultimate consumer product––a highly personal space that should enhance and reflect the lives of the people who live there. Grounded in this consumer-first focus, Veev has pioneered a breakthrough technological approach to building turnkey, high-quality homes faster and at a lower cost than traditional construction.

    "Gordon's business acumen and strategic leadership experience align seamlessly with Veev's expansion efforts and will be a major asset for our company," said Amit Haller, Veev CEO and co-founder. "His career is noteworthy, not only for his success in driving strong financial performance, but also for his track record of leading diverse, capable, and innovative teams. At Veev, we're tackling one of the most challenging issues facing the world today, and bringing aboard leaders like Gordon advances our mission to bring exceptional living to all."

    Heneweer joins Veev at a time of rapid growth for the company, having recently achieved unicorn status, raised $400 million in Series D financing, and announced a major partnership with Lennar. Now, the company remains focused on scaling operations by replicating its successful wheel-and-spoke model, or "Fab-in-a-Box," to new markets. The strategy, which capitalizes on building Digital Fab facilities near demand, allows the company to streamline manufacturing, transportation, and assembly––building up to 4x the speed and at a fraction of the cost of traditional means.

    "Veev has created a revolutionary approach to solving the housing crisis, leveraging cutting-edge technology and developing a unique vision for what the home should be," said Gordon Heneweer. "I'm eager to get to work alongside this brilliant team, and I look forward to advancing Veev's bold vision for the future of homebuilding and how we experience the home."

    Prior to Veev, Heneweer served as CFO for the past 10 years at CooperVision (NYSE:COO), a $2B+ revenue medical device manufacturer and distributor. He was a key member of CooperVision's executive leadership team, leading and directing all aspects of the organizations' financial strategy and operations, including oversight of the global IT function. Gordon's esteemed career also includes senior financial leadership positions of increasing responsibility at Electronics for Imaging, Inc., Applied Materials, Inc., and New United Motor Manufacturing, Inc. (NUMMI).

    To learn more about Veev, visit https://veev.com/.

    About Veev

    Veev is a building technology company founded on the belief that homes are the ultimate consumer product, and they need to be built better, and faster. Working across design, development, engineering, manufacturing, and construction, Veev has developed a vertically integrated approach to productize the home and improve on cost and quality, up to 4x the speed of traditional construction. Veev is focused on building multi-family homes and single-family homes at scale, helping develop and support communities, and improving our quality of living.

    Contact

    LaunchSquad for Veev

    veev@launchsquad.com

     



    Primary Logo

    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    3/4/2026$85.00Buy → Neutral
    Rothschild & Co Redburn
    2/3/2026$100.00 → $99.00Buy
    Needham
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    10/13/2025$85.00Overweight
    Barclays
    10/1/2025$64.00Sell
    Goldman
    8/28/2025$72.00Buy → Neutral
    Citigroup
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    More analyst ratings

    $COO
    SEC Filings

    View All

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/29/26 4:26:32 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/4/26 4:30:44 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    4/8/26 4:53:52 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Rosebrough Walter M Jr

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/21/26 5:45:31 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Weiss Robert S

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:40 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Rivas Maria

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:25 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00

    3/4/26 8:35:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Needham reiterated coverage on Cooper with a new price target

    Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously

    2/3/26 7:02:57 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cooper from Overweight to Equal Weight and set a new price target of $72.00

    11/13/25 8:26:09 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperVision Names Muru Annamalai as President, Asia-Pacific

    Experienced Global Healthcare Leader to Guide Growth Across the RegionSINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1, 2026. He brings more than two decades of global leadership experience across the pharmaceutical and healthcare sectors, with extensive expertise leading commercial organizations and driving growth across Asia-Pacific, Latin America, and other global markets. His appointment reflects CooperVision's broader investment in guiding the company's next phase of growth across one of its most dynamic and strategically important regions.

    5/29/26 8:05:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    CooperCompanies Announces Release Date for Second Quarter 2026

    SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beauti

    4/30/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Release Date for Second Quarter 2026

    SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beauti

    4/30/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces First Quarter 2026 Results

    SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,

    3/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care